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The role of the endocrine hormone leptin in controlling energy homeostasis in the
hypothalamus are well documented. However the CNS targets for leptin are not
restricted to the hypothalamus as a high density of leptin receptors are also expressed
in several parts of the brain involved in higher cognitive functions including the
hippocampus. Numerous studies have identified that in the hippocampus, leptin has
cognitive enhancing actions as exogenous application of this hormone facilitates
hippocampal-dependent learning and memory, whereas lack or insensitivity to leptin
results in significant memory deficits. Leptin also markedly influences some of the main
cellular changes that are involved in learning and memory including NMDA-receptor
dependent synaptic plasticity and glutamate receptor trafficking. Like other metabolic
hormones, there is a significant decline in neuronal sensitivity to leptin during the ageing
process. Indeed, the capacity of leptin to modulate the functioning of hippocampal
synapses is substantially reduced in aged compared to adult tissue. Clinical studies
have also identified an association between circulating leptin levels and the risk of certain
neurodegenerative disorders such as Alzheimer’s disease (AD). In view of this, targeting
leptin and/or its receptor/signaling mechanisms may be an innovative approach for
developing therapies to treat AD. In support of this, accumulating evidence indicates
that leptin has cognitive enhancing and neuroprotective actions in various models of
AD. Here we assess recent evidence that supports an important regulatory role for
leptin at hippocampal CA1 synapses, and we discuss how age-related alterations in
this hormonal system influences neurodegenerative disease.
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LEPTIN AND LEPTIN RECEPTORS
Leptin, an endocrine hormone, is the functional product of the obese (ob) gene. It is principally
made in white adipose tissue and once secreted, the circulating levels of leptin correlate directly to
body fat content (Maffei et al., 1995; Considine et al., 1996). The fasting leptin levels that circulate
in the plasma generally range from 1 ng/ml to 100 ng/ml (Boden et al., 1996). Peripherally-
derived leptin readily accesses the brain via a transport mechanism that is saturable and highly
sensitive to triglycerides and adrenaline (Banks et al., 2004). Hypothalamic neural circuits are a
key site for the central actions of leptin with the arcuate nucleus in particular being crucial for
the energy regulating functions of this hormone. However, the neuronal actions of leptin extend
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beyond the hypothalamus, with many areas of the brain
including the hippocampus and cerebral cortex expressing leptin
receptors at a high density.
Leptin receptors are produced by the diabetes (db) gene
and six isoforms of the leptin receptor, ObRa-f, exist. All the
isoforms, with the exception of ObRe, are expressed at the
plasma membrane, have analogous extracellular domains, but
differ in the length of their intracellular domain. The intracellular
domain of the short isoforms (ObRa, c, d, f) range from
30 to 40 amino acid residues in length. Contrastingly, the
long isoform, ObRb incorporates an extended (302 residues)
intracellular domain, which enables the full complement of
leptin receptor signaling pathways to be activated by this
isoform. In contrast, the short isoforms have limited capacity
to signal, with only some of the Ob-Rb-driven signaling
molecules being activated by the short isoforms. ObRe is a
novel leptin receptor isoform as it does not have a membrane
spanning region, but it readily binds leptin. Consequently,
leptin binding to ObRe is thought to aid its transport in the
plasma.
Leptin receptors are highly homologous to other class
I cytokine receptors; a superfamily of receptors that
includes interferon receptors. Leptin binding to ObR
activates janus tyrosine kinase 2 (JAK2), which promotes
JAK2 phosphorylation. This in turn allows particular tyrosine
residues located intracellularly to be phosphorylated. This
sequence of events enables a number of signaling pathways to
be activated by ObRs. The principle signaling molecules that are
stimulated by neuronal ObRs include the signal transduction
and activator of transcription (STAT) transcription factors,
phosphoinositide-3 kinase (PI 3-kinase) and mitogen-activated
protein kinase (MAPK; Farooqi and O’Rahilly, 2014).
LEPTIN REGULATION OF HIPPOCAMPAL
SYNAPTIC FUNCTION
Anatomical evaluation of ObR expression in the brain has
detected a high density of this receptor in different regions
of the hippocampus and specifically at hippocampal synapses
(Hâkansson et al., 1998; Shanley et al., 2002). In line with this
expression pattern, leptin treatment potently regulates excitatory
synaptic transmission evoked at hippocampal Schaffer-collateral
(SC)-CA1 synapses (Shanley et al., 2001; Oomura et al., 2006;
Moult et al., 2010; Moult and Harvey, 2011). Moreover, studies
in obese rodents that are leptin-insensitive have also identified
significant impairments in two key forms of hippocampal
synaptic plasticity, namely long-term potentiation (LTP) and
long-term depression (LTD). Additionally, marked deficits in
behavioral assessment of hippocampal-dependent memory have
also been reported in these obese rodents (Li et al., 2002;Winocur
et al., 2005). Together these findings support the notion that
leptin has potential cognitive enhancing actions.
More recent studies indicate that application of leptin also
influences the magnitude of excitatory synaptic transmission at
another synaptic input to CA1 neurons. This input, which arises
in the entorhinal cortex (EC), forms part of the temporoammonic
(TA) pathway (Luo et al., 2015; McGregor et al., 2018; Figure 1).
Indeed, application of leptin to juvenile (11–18) hippocampal
slices induces LTP at this synaptic connection (Luo et al., 2015),
which directly contrasts with the leptin-induced depression
of synaptic transmission observed at SC-CA1 synapses at
this age (Moult and Harvey, 2011). Interestingly, although
leptin has divergent actions at the two synaptic inputs to
pyramidal neurons, activation of NMDA receptors is essential
for both forms of leptin-dependent synaptic plasticity (Moult
and Harvey, 2011; Luo et al., 2015). The involvement
of NMDA receptors parallels the dependance on NMDA
receptors for other key modulatory effects of leptin in the
hippocampal formation. For instance, the ability of leptin
to rapidly increase the density of hippocampal dendritic
filopodia is dependent on NMDA receptor activation as
the morphological changes induced by leptin are diminished
in the presence of the NMDA receptor antagonist, D-AP5
(O’Malley et al., 2007). Similarly, a requirement for NMDA
receptors has been demonstrated for the leptin-driven reversal
of LTP (known as depotentiation) as this process is blocked
following antagonism of NMDA receptors. In the thalamic-
lateral amygdala pathway, NMDA receptors are also required for
the depotentiation of amygdala LTP induced by leptin (Wang
et al., 2015). Interestingly recent studies indicate that NMDA
receptors, and specifically GluN2B-containing NMDA receptors
in hypothalamic AgRP neurons, are critically involved in leptin-
dependent homeostatic control of body weight (Üner et al.,
2015).
LEPTIN REGULATION OF AMPA
RECEPTOR TRAFFICKING
Synaptic insertion and removal of AMPA receptors is known
to be important for driving long term alterations in excitatory
synaptic efficacy at hippocampal synapses (Collingridge et al.,
2004; Herring and Nicoll, 2016). Transient changes in the
molecular identity of synaptic AMPA receptors following LTP
induction has been detected in some studies (Plant et al.,
2006; Morita et al., 2014), but there are some exceptions
(Tang et al., 1999; Clayton et al., 2002). In a similar manner,
leptin promotes insertion of AMPA receptors into hippocampal
synapses, and this is pivotal for leptin driven changes in
synaptic efficacy (e.g., LTP) at adult hippocampal SC-CA1
synapses (Moult et al., 2010). Thus, the rectification index
of synaptic AMPA receptors is enhanced by leptin, and
addition of philanthotoxin, to selectively inhibit GluA2-lacking
AMPA receptors, results in reversal of LTP induced by leptin.
Together this suggests that incorporation of GluA2-lacking
AMPA receptors into synapses is a key mechanism underlying
leptin-induced LTP (Moult et al., 2010). In agreement with
this, studies using a combination of immunocytochemical
and biotinylation techniques have demonstrated that exposure
to leptin increases the plasma membrane expression of
the AMPA receptor GluA1 subunit in primary cultures of
hippocampal neurons and in hippocampal slices (Moult et al.,
2010).
Trafficking of AMPA receptors is also essential for the
reported effects of leptin at TA-CA1 synapses (Figure 1).
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FIGURE 1 | Activation of leptin receptors influences hippocampal synaptic efficacy at temporoammonic (TA)-CA1 synapses. Schematic representation of the
predominant signaling pathways that are activated by leptin receptors located at hippocampal TA-CA1 synapses. Leptin binding to ObRb results in phosphorylation
of janus tyrosine kinase 2 (JAK2) which in turn promotes phosphorylation and dimerization of signal transducer and activator of transcription 3 (STAT3), leading to
gene transcriptional changes in the nucleus. Activation of JAK2-STAT3 signaling mediates leptin-induced AMPA receptor internalization and induction of long-term
depression (LTD) at adult TA-CA1 synapses. The ability of leptin to induce LTD at adult TA-CA1 synapses also requires the activation of GluN2A-containing NMDA
receptors, which also promotes the removal of AMPA receptors from hippocampal synapses. In contrast, at juvenile TA-CA1 synapses, leptin-driven stimulation of the
phosphoinositide-3 kinase (PI 3-kinase) cascade, culminates in the synaptic insertion of AMPA receptors and the induction of long-term potentiation (LTP). Activation
of GluN2B NMDA receptor subunits is pivotal for leptin-induced LTP and the synaptic insertion of GluA2-lacking AMPA receptors at juvenile TA-CA1 synapses.
Indeed, application of philanthotoxin also reverses the
persistent increase in synaptic transmission induced by
leptin at juvenile TA-CA1 synapses, suggesting that GluA2-
lacking AMPA receptor are inserted into synapses by leptin
and that this process is required for leptin-induced LTP
(Luo et al., 2015). Conversely, the synaptic removal of
GluA2-lacking AMPA receptors is implicated in leptin-
induced LTD as leptin fails to induce LTD in the presence
of selective inhibitors of clathrin-mediated endocytosis
(McGregor et al., 2018). In a manner similar to SC-CA1
synapses, application of leptin is not only capable of inducing
LTD but this also results in a significant reduction in
GluA1 surface expression in hippocampal slices (McGregor
et al., 2018).
Significant evidence indicates that activity-dependent LTP
and LTD is likely to be key cellular events that underlie learning
and memory processes that are hippocampus-dependent
(Bliss and Collingridge, 1993). Moreover, occlusion studies
have demonstrated that leptin-induced changes in excitatory
synaptic strength evoked at SC-CA1 and TA-CA1 synapses
occlude activity-dependent synaptic plasticity, indicating similar
expression mechanisms (Moult and Harvey, 2011; Luo et al.,
2015; McGregor et al., 2018). Thus, as leptin induces novel
forms of synaptic plasticity, and regulates AMPA receptor
trafficking processes, which mirrors the cellular processes that
are implicated in hippocampal-dependent learning and memory,
it suggests that leptin has cognitive enhancing properties.
PROTECTIVE ACTIONS OF LEPTIN IN THE
CNS
A possible protective role for leptin in the CNS was first
suggested in comparative studies that identified significant
brain changes in leptin deficient ob/ob mice compared to their
wildtype littermates (Ahima et al., 1999). In these studies,
the brain weight of ob/ob mice was markedly lower than
wildtype mice suggesting that lack of leptin reduces neuronal
viability (Ahima et al., 1999). In support of this, treatment
of ob/ob mice with leptin for up to 4 weeks completely
reversed the observed brain abnormalities (Ahima et al., 1999).
Numerous subsequent studies support the notion that leptin
has protective actions centrally. Thus studies performed in
central and peripheral neurons indicate that exposure to leptin
not only enhances the rate of neuronal survival, but also
prevents neuronal cell death induced by a variety of apoptotic
stimuli (Doherty et al., 2008; Guo et al., 2008; Davis et al.,
2014).
Protective effects of leptin have been shown in several
CNS-driven disease models that are associated with neuronal
apoptosis. In a mouse model of cerebral ischemia, treatment
with leptin decreased the extent of brain injury as the overall
infarct volume was attenuated by leptin (Zhang et al., 2013).
Similarly, in an oxygen/glucose deprivation model of ischemia,
leptin protects against ischemic damage (Zhang and Chen, 2008).
In various models of Parkinson’s disease (PD), the viability
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of dopaminergic neurons treated with either 6-OH dopamine
or MPTP is significantly enhanced after treatment with leptin
(Weng et al., 2008; Doherty et al., 2008). Moreover, prior
exposure of human SH-SY5Y neuroblastoma cells with leptin
also prevented neuronal cell death induced by the neurotoxin
1-methyl-4-pyridinium (MPP+; Lu et al., 2006).
It is interesting to note that the neuroprotective properties
of metabolic hormones is not restricted to leptin. Thus,
ghrelin, which is produced in the stomach and regulates body
weight by promoting food intake, also markedly influences
neuronal viability (de Candia and Matarese, 2018). In
hypothalamic cells, treatment with ghrelin protects against
oxygen-glucose deprivation and subsequent apoptosis by
inhibiting mitochondrial formation of reactive oxygen species
(Chung et al., 2007). The toxic apoptotic actions of Aβ are
also attenuated in hypothalamic cells and hippocampal neurons
following treatment with ghrelin (Moon et al., 2011; Gomes et al.,
2014). Moreover, in a mouse model of traumatic brain injury,
ghrelin limits the degree of neuronal degeneration by reducing
apoptosis (Lopez et al., 2014). Recent evidence indicates that like
leptin, age-related alterations occur in ghrelin function which
are thought to lead to an increased risk of neurodegenerative
disease (de Candia and Matarese, 2018). As both these metabolic
hormones have comparable neuroprotective actions in the
hippocampus, and given their closely related hypothalamic
functions, it is feasible that there is some cross-talk between
the hormones in terms of neuroprotective mechanisms.
Although evidence of this is limited, leptin and ghrelin are
both reported to prevent Aβ-induced cell death via inhibition
of GSK-3β (Martins et al., 2013). However, further studies
are required to examine potential interactions between these
metabolic hormones and in turn how this impacts on CNS
health.
LEPTIN AND AGING
It is known that as individuals get older, the functioning of
metabolic hormones deteriorates and this has implications for
normal CNS function as metabolic dysfunction has been linked
to faster ageing and an increased likelihood of developing
neurodegenerative conditions such as Alzheimer’s disease (AD;
Stranahan and Mattson, 2011; Kim and Feldman, 2015). Several
lines of evidence support the notion that age-related changes in
the effectiveness of the leptin system occurs in the CNS. Indeed,
hypothalamic neurons are less responsive to leptin with age as the
satiety effects of leptin are markedly reduced in aged (30 month)
compared to adult (6 month) rats (Shek and Scarpace, 2000).
At the cellular level, reductions in leptin-driven activation of
STAT3 as well as phosphorylated-STAT3 binding activity have
been observed in aged rats (Shek and Scarpace, 2000; Scarpace
et al., 2001). Attenuated uptake of leptin into the hypothalamus,
as well as reductions in the capacity of ObRs to signal, due to
elevations in suppressor of cytokine signaling-3 (SOCS-3), have
also been reported in aged animals (Wang et al., 2001; Peralta
et al., 2002).
Age-dependent changes in response to leptin have also
been detected at hippocampal synapses. At juvenile (P14–21)
SC-CA1 synapses, treatment of hippocampal slices with leptin
markedly depresses excitatory synaptic transmission, however
this effect is transient as it is readily reversed on leptin
washout (Shanley et al., 2001; Xu et al., 2008; Moult and
Harvey, 2011). In contrast, leptin has directly opposing actions
in hippocampal slices obtained from adult (3–4 months)
rats as exposure to leptin culminates in LTP induction at
SC-CA1 synapses. Moreover the magnitude of leptin-induced
LTP at SC-CA1 synapses is significantly altered with age,
as leptin-induced LTP is attenuated by around 50% in aged
(12–14months) relative to adult tissue (Moult andHarvey, 2011).
Thus, not only does leptin have bi-directional age-dependent
effects on synaptic efficacy at excitatory SC-CA1 synapses, but
there is also a marked reduction in the sensitivity to leptin
with age.
Recent evidence indicates that the modulatory actions of
leptin at excitatory TA-CA1 synapses is also highly dependent
on age (McGregor et al., 2018; Figure 1; Table 1). In juvenile
tissue, application of leptin leads to TA-CA1 LTP (Luo et al.,
2015), whereas a persistent depression (LTD) is observed after
leptin addition to adult hippocampal slices (McGregor et al.,
2018). Moreover like SC-CA1 synapses, the leptin-sensitivity
of TA-CA1 synapses markedly decreases in aged tissue, as
application of leptin fails to induce LTD at aged TA-CA1
synapses (McGregor et al., 2018). It is unclear why leptin has
no effect at aged excitatory TA-CA1 synapses. However the lack
of leptin responsiveness is unlikely to be due to age-related
changes in NMDA receptor expression as TA-CA1 LTP is
readily induced by a high frequency stimulation protocol in
slices from aged animals, and like leptin-induced LTD, the
cellular mechanisms underlying TA-CA1 LTP are dependent
on GluN2A-containing NMDA receptors (McGregor et al.,
2018).
Studies examining the potential cellular mechanisms
contributing to the age-dependent actions of leptin have
evaluated the role of NMDA receptors, as hippocampal
NMDA receptors comprising different NMDA receptor
subunits are implicated in divergent types of synaptic
plasticity (Liu et al., 2004; Bartlett et al., 2007), and NMDA
receptor expression and molecular identity varies at different
stages of development and ageing (Monyer et al., 1994).
Using pharmacological tools to selectively block different
GluN2 subunits, it has been shown that distinct NMDA
receptor subunits contribute to the bi-directional and age-related
actions of leptin at hippocampal synapses. Thus, NMDA
receptors comprised of GluN2B subunits mediate the leptin-
driven synaptic depression at juvenile SC-CA1 synapses. By
contrast, in adult hippocampus, activation of NMDA receptors
that contain GluN2A subunits is key for the induction of
LTP by leptin at SC-CA1 synapses. (Moult and Harvey,
2011). At TA-CA1 synapses, NMDA receptors with distinct
molecular composition are also implicated in the opposing
age-dependent effects of leptin. Thus, activation of GluN2B
subunits is required for leptin-induced LTP in juvenile tissue
(Luo et al., 2015) whereas GluN2A subunits underlie leptin-
induced LTD in adult hippocampus (McGregor et al., 2018;
Table 1). The signaling pathways that link leptin receptor
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TABLE 1 | Summary of the opposing actions of leptin at hippocampal synapses
with age.
SC-CA1 synapse TA-CA1 synapse
Juvenile (P11–18) hippocampal slices
Leptin-induced synaptic
depression
Leptin-induced LTP
GluN2B-dependent GluN2B-dependent
ERK signaling PI 3-Kinase signaling
Removel of GluA2-lacking
AMPARs
Insertion of GluA2-lacking
AMPARs
Adult (3–6 months) hippocampal slices
Leptin-induced LTP Leptin-induced LTD
GluN2A-dependent GluN2A-dependent
PI 3-Kinase signaling JAK2-STAT3 signaling
Insertion of GluA2-lacking
AMPARs
Removel of GluA2-lacking
AMPARs
Aged (12–15 months) hippocampal slices
Leptin-induced LTP Leptin fails to induce LTD
Magnitude of leptin-induced LTP
is reduced.
LFS also fails to induce LTD
Summary table illustrating the bi-directional effects of the hormone leptin
at hippocampal Schaffer-collateral (SC)-CA1 and temporoammonic (TA)-CA1
synapses. At juvenile SC-CA1 synapses, application of leptin results in a
transient depression of excitatory synaptic transmission that is not only NMDA
receptor dependent but involves selective activation of GluN2B-containing NMDA
receptors. In addition, activation of an ERK-dependent process and subsequent
removal of GluA2-lacking AMPA receptors underlies this effect of leptin. Conversely
at adult (3–6 months) SC-CA1 synapses, a novel form of long-term potentiation
(LTP) is evoked by leptin. This process is GluN2A-dependent, requires activation of
phosphoinositide-3 kinase (PI 3-kinase) and the synaptic insertion of GluA2-lacking
AMPA receptors. The ability of leptin to regulate SC-CA1 synapses markedly
declines with age as the magnitude of leptin-induced LTP at SC-CA1 synapses
is significantly attenuated in aged hippocampus. At all stages of development
and ageing, leptin has opposing actions on synaptic efficacy at the anatomically
distinct TA input to CA1 neurons. Thus in contrast to its actions at SC-CA1
synapses, leptin induces a novel form of NMDA-dependent LTP at juvenile
TA-CA1 synapses. Leptin-induced LTP involves selective activation of GluN2B
subunits and PI 3-kinase-driven trafficking of GluA2-lacking AMPA receptors to
synapses. In contrast, application of leptin to adult hippocampal slices leads to
the induction of a novel form of NMDA receptor-dependent long-term depression
(LTD) at TA-CA1 synapses. Leptin-induced LTD is GluN2A-dependent and involves
activation of canonical janus tyrosine kinase 2 (JAK2)-signal transducer and
activator of transcription 3 (STAT3) signaling and internalization of GluA2-lacking
AMPA receptors. Like SC-CA1 synapses, there is a marked reduction in the
sensitivity of TA-CA1 synapses with age, as leptin fails to induce LTD at aged
TA-CA1 synapses.
activation to modulation of synaptic efficacy also differ
depending on age and synaptic connection. Thus, at adult
SC-CA1 synapses, PI3-kinase activation is crucial for leptin-
induced LTP, but stimulation of ERK-dependent signaling
is essential for the synaptic depression induced by leptin at
juvenile slices. Interestingly, divergent signaling pathways
also mediate the age-related modulatory actions of leptin
at TA-CA1 synapses as LTP induce by leptin at juvenile
synapses requires GluN2B subunits and PI 3-kinase-driven
signaling (Luo et al., 2015; Figure 1). However in adult,
leptin-induced TA-CA1 LTD is unique as JAK2-STAT3
signaling which in turn drives gene transcriptional changes are
fundamental for this form of synaptic plasticity (McGregor
et al., 2018; Figure 1). Overall these data suggest that
the age-dependent effects of leptin on excitatory synaptic
transmission at the two distinct inputs to CA1 pyramidal
neurons are dependent on the molecular composition of NMDA
receptors.
LEPTIN AND ALZHEIMER’S DISEASE
Age significantly increases the risk of developing AD, and
as a consequence the prevalence of this disease is steadily
increasing as people live longer. Other prominent factors that
influence AD risk, include diet and lifestyle. Indeed, mid-life
obesity significantly alters the risk of AD later in life, when
compared to individuals with normal body weight. Increased
body fat content results in higher circulating levels of leptin
and subsequent development of leptin resistance in the obese
state (Friedman, 2014). Thus AD risk may also be significantly
altered in individuals with resistance to leptin and/or altered
responsiveness to leptin. In support of this notion, attenuated
levels of leptin in the plasma are documented in AD patients
(Power et al., 2001), and prospective studies have found that
low leptin levels is linked to an elevated risk of AD with
age (Lieb et al., 2009). The fact that very high leptin levels
(and subsequent development of leptin resistance) as well as
low leptin levels are both associated with an increased risk
of AD suggests that divergent metabolic states can influence
the risk of AD. Although these clinical findings appear to
be contradictory, there are parallels to the regulatory actions
of leptin in the hypothalamus. Thus, the ability of leptin to
regulate food intake and body weight occurs within a tightly
regulated concentration range, such that too little circulating
leptin fails to influence energy homeostasis, whereas highly
elevated leptin levels that occur in the obese state not only results
in leptin resistance but also loss of leptin’s capacity to regulate
food intake (Friedman, 2014). Overall this suggests that failure
to maintain normal body weight and thus keep leptin levels
within the physiological range, results in an increased risk of
developing AD.
In a manner similar to AD patients, alterations in leptin
function have also been observed in several rodent models of
AD. Indeed transgenic models that have the same mutations
that occur in familial AD, also exhibit reduced circulating
leptin levels, suggesting compromised leptin function (Fewlass
et al., 2004). However some clinical studies have found no
apparent link between plasma leptin levels and AD. One
possible reason for this discrepancy is that the plasma levels
of leptin may not be a good indicator of leptin levels in
the CNS. Indeed, altered blood-brain transport of leptin has
been documented in AD (Dietrich et al., 2008), suggesting
that the CNS levels of leptin are reduced in AD compared
to normal. However, studies that have directly measured the
brain levels of leptin have reported increased or unaltered
leptin levels in AD patients (Bonda et al., 2014; Maioli et al.,
2015). However, attenuated expression of leptin receptor mRNA
and immunoreactivity is evident in post-mortem AD tissue,
suggesting possible development of resistance to leptin (Bonda
et al., 2014; Maioli et al., 2015). Reductions in some key signaling
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FIGURE 2 | Leptin prevents the key pathological changes in Alzheimer’s disease (AD). Schematic representation of the protective actions of leptin in AD. Toxic forms
of Aβ are formed by the proteolytic processing of APP by the enzyme BACE1. Leptin limits production of Aβ in neurons via inhibiting BACE1 activity. Leptin also
attenuates extracellular Aβ levels by promoting the clearance and degradation of Aβ. Accumulation of Aβ promotes assembly of fibrillary forms of Aβ that leads to
formation amyloid plaques. Leptin reduces plaque formation by reducing expression of GM1 gangliosides thereby limiting assembly of fibrillary Aβ. Leptin also
counteracts the harmful effects of Aβ as it protects against the toxic actions of Aβ via stimulation of pro-survival signaling pathways. Hyper-phosphorylation of tau
protein occurs in AD which results in formation of neurofibrillary tangles. GSK-3β drives phosphorylation of tau, and leptin limits this via inhibiting the activity of
GSK-3β.
pathways that are activated downstream of leptin receptors have
been observed in AD tissue which also supports the possibility
that central resistance to leptin develops in AD (Maioli et al.,
2015).
PROTECTIVE ACTIONS OF LEPTIN IN AD
MODELS
Increasing evidence indicates that leptin has protective actions in
a variety of cellular systems thatmodel the neuronal degeneration
that occurs in AD. Several studies have revealed that the levels of
toxic Aβ are diminished after treatment with leptin (Figure 2).
Indeed, the activity of β secretase, a key enzyme involved in the
production of Aβ1–42, is reduced by leptin resulting in decreased
levels of Aβ1–42 (Fewlass et al., 2004). In H4 neuroglioma cells,
transcription of presenilin 1 is also down-regulated by leptin
which in turn leads to attenuated Aβ1–42 levels (Niedowicz
et al., 2013). Uptake of Aβ is also modulated by leptin as
LRP1-mediated uptake of Aβ is elevated after treatment of
human SHSY-5Y neuroblastoma cells with leptin (Fewlass et al.,
2004). Furthermore, leptin enhances the degradation of Aβ by
increasing the levels of insulin degrading enzyme in organotypic
brain slices (Marwarha et al., 2010).
In neurotoxicity assays, exposure of hippocampal or cortical
neurons to leptin protects against the harmful actions of
oligomeric Aβ on neuronal viability (Doherty et al., 2013;
Martins et al., 2013; Figure 2). Leptin also prevents the
increased aggregation of Aβ that occurs after treatment of
cortical neurons with Cu2+ ions (Doherty et al., 2013). In
addition, leptin is reported to have neuroprotective actions in
hypothalamic cells, as the ability of oligomeric Aβ to increase
superoxide production and elevate intracellular calcium levels are
significantly attenuated by leptin in mHypoE-N42 cells (Gomes
et al., 2014).
It is known that increased expression of the presynaptic
protein, endophilin 1 occurs in those suffering from AD and
in transgenic AD models (Ren et al., 2008). As endophilin
1 inhibits the synaptic release of glutamate (Weston et al.,
2011), AD-linked increases in endophilin 1 are likely to
have a direct impact on excitatory synaptic transmission.
Recent evidence has demonstrated that exposure to leptin
also alters expression of endophilin1, as leptin inhibits the
increase in endophilin 1 induced by Aβ (Doherty et al.,
2013). Moreover, the cortical levels of endophilin 1 are
up-regulated in Zucker fa/fa rats which indicates that
insensitivity to leptin elevates the brain levels of endophilin
1 in vivo (Doherty et al., 2013). Consequently it is possible,
that leptin, by regulating endophilin 1 expression, indirectly
influences excitatory synaptic transmission at hippocampal
synapses.
In addition to preventing the chronic actions of Aβ,
leptin is also capable of directly influencing the impact
of acute Aβ on hippocampal synaptic function. It is well
established that short-term treatment with Aβ not only results
in inhibition of activity-dependent LTP, but it also enhances
LTD in hippocampal slices (Shankar et al., 2008; Li et al.,
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2009). Moreover exposure to leptin is reported to reverse
Aβ-driven inhibition of hippocampal LTP and it prevents
facilitation of LTD induced by Aβ (Doherty et al., 2013;
Malekizadeh et al., 2017). Direct effects of Aβ on AMPA
receptor trafficking processes have also been observed, such
that treatment with Aβ promotes internalization and synaptic
removal of GluA1 subunits in hippocampal cultures (Li
et al., 2009; Doherty et al., 2013). Prior treatment with
leptin also counteracts this detrimental effect of Aβ as
the ability of Aβ to internalize GluA1 subunits is blocked
by leptin (Doherty et al., 2013; Malekizadeh et al., 2017).
PI 3-kinase activation is required for the protective effects
of leptin as pharmacological inhibition of this signaling
cascade blocked the ability of leptin to prevent the acute
actions of Aβ on hippocampal synapses (Doherty et al.,
2013).
It has been proposed that oligomeric Aβ facilitates the
induction of LTD via preventing uptake of glutamate at
hippocampal synapses (Li et al., 2009). This process is
likely to enhance glutamate levels within the synaptic cleft
leading to activation and subsequent desensitization of synaptic
NMDA receptors (Li et al., 2009). One of the proposed
functions of LTD is to enhance the flexibility of networks
by providing a way of re-setting potentiated synapses, thereby
preventing saturation of hippocampal synapses which would
limit capacity for learning. However this normal function of
LTD is likely to be compromised in AD, as hippocampal
synapses exposed to Aβ are unable to be potentiated/saturated
due to the block of LTP induction by Aβ. Consequently in
AD, hippocampal excitatory synapses are likely to remain
in a depressed state; an effect that would be reinforced
by sustained removal of AMPA receptors from synapses by
Aβ. As treatment with leptin prevents the aberrant effects
of Aβ on hippocampal LTP and LTD, as well as AMPA
receptor trafficking, it is likely that restoration of normal
hippocampal synaptic function would occur after treatment with
leptin.
However, as leptin also has direct effects on excitatory
synaptic efficacy, including its ability to induced novel forms of
LTP and LTD at hippocampal synapses, do the protective actions
of leptin have a bearing on its potential cognitive enhancing
properties?What is clear is that the ability of leptin to prevent the
acute synapto-toxic actions of Aβ occurs at low concentrations
of leptin that have little or no effect of basal excitatory synaptic
transmission (Doherty et al., 2013). In contrast, however, the
marked effects of leptin on hippocampal synaptic plasticity that
are likely to enhance cognition, occur at much higher leptin
concentrations. This suggests that the protective and cognitive
enhancing actions of leptin are distinct, as they have differing
pharmacological profiles.
LEPTIN INFLUENCES TAU-RELATED
PATHOLOGY IN AD
Neurofibrillary tangles are another major feature of AD
pathology and hyper-phosphorylated tau is a key element of
these tangles. Increasing evidence suggests that leptin limits
accumulation of tau within the brain. Indeed, significantly
lower phosphorylated tau (p-tau) levels are detected in
TgCRND8 mice, that overexpress mutant human APP, after
treatment with leptin (Greco et al., 2010). Tau phosphorylation
status is also directly reduced by leptin as the activity of GSK3β,
a key enzyme that drives tau phosphorylation, is inhibited by
this hormone (Greco et al., 2009, 2010; Figure 2). Cortical
neurons that are chronically treated with Aβ also exhibit
elevated levels of p-tau and this process is markedly reduced
by leptin (Doherty et al., 2013). In addition, impaired leptin
function is associated with alterations in cortical p-tau levels
in vivo as markedly elevated levels of p-tau have been detected
in leptin-insensitive Zucker fa/fa rats (Doherty et al., 2013).
Moreover, development of leptin resistance has recently been
associated with enhanced tau pathology in mouse models of
AD (Platt et al., 2016). Thus it is clear that leptin not only
limits phosphorylation of tau, but also that lack of leptin
receptor-driven signaling increases p-tau levels which lends
support to the hypothesis that AD risk is influenced by
impairments in the leptin system (Power et al., 2001; Lieb et al.,
2009).
LEPTIN IMPROVES MEMORY IN AD
MODELS
Significant evidence indicates that activity-dependent LTP and
LTD are likely to be key cellular events that underlie learning
and memory processes that are hippocampus-dependent
(Bliss and Collingridge, 1993). Moreover, occlusion studies
have demonstrated that leptin-driven changes in excitatory
synaptic strength evoked at SC-CA1 and TA-CA1 synapses
occlude activity-dependent synaptic plasticity, indicating similar
expression mechanisms (Moult and Harvey, 2011; Luo et al.,
2015; McGregor et al., 2018). Thus, as leptin induces novel
forms of synaptic plasticity, and it potently regulates AMPA
receptor trafficking processes, both of which mirror the cellular
processes that are implicated in hippocampal-dependent
learning and memory, it suggests that leptin has cognitive
enhancing properties. Indeed, this is backed up in numerous
behavioral studies which demonstrate that leptin has cognitive
enhancing effects in rodents. Indeed intravenous administration
of leptin facilitates performance in hippocampal spatial memory
tests assessed using the Morris water-maze (Oomura et al.,
2006). Conversely, deficits in hippocampal-dependent spatial
memory are observed in leptin-insensitive rodents, suggesting
that insensitivity to leptin markedly influences hippocampal-
dependent memory (Li et al., 2002; Winocur et al., 2005).
Diet-induced leptin resistance also interferes with memory
consolidation in rats, such that marked deficits are observed
in object recognition tests in diet-induced obese rats compared
to wild type mice with normal body weight (Zanini et al.,
2017).
Application of leptin also enhances performance in many
hippocampal-dependent memory tasks in rodent models of
AD. Thus, in SAMP8 mice which have elevated levels of Aβ
and hippocampal memory deficits, administration of leptin
improves performance in a T-maze task (Farr et al., 2006). In
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TgCRND8 mice, a transgenic line derived from an APP Swedish
mutation that develop amyloid plaques in the hippocampus and
cortex from 9 weeks of age, treatment with leptin enhances the
ability to perform behavioral tests of novel object recognition
and fear conditioning (Greco et al., 2010). Hippocampal
memory deficits in APP/PS1 mice have also been reversed
by intracerebroventricular (ICV) administration of a lentiviral
vector expressing leptin (Pérez-González et al., 2014). Recent
in vivo studies also support the notion that leptin counteracts
the harmful actions of Aβ on hippocampal-dependent memory,
as the spatial memory deficits induced by ICV application of
Aβ(1–42) are alleviated in rats exposed to leptin (Tong et al.,
2015). Thus, there is clear evidence that treatment with leptin
enhances cognition in both healthy animals and in models
of AD.
THE THERAPEUTIC POTENTIAL OF THE
LEPTIN SYSTEM IN AD
Although leptin has cognitive enhancing and neuroprotective
actions in rodents, it is key for future development of leptin as an
AD therapy, that its central actions in humans are well defined.
Several studies have observed cognitive enhancing actions of
leptin in human clinical studies. Thus, significant increases in
gray matter volume have been detected in adults with congenital
leptin deficiencies following treatment with physiological levels
of leptin (Matochik et al., 2005). Leptin replacement therapy has
also led to a significant improvement in cognitive function in a
5 year old with leptin deficiency due to a rare ob gene mutation
(Paz-Filho et al., 2008). Although chronic leptin replacement
therapy is safe and well tolerated in humans (Paz-Filho et al.,
2015), there have been no clinical trials carried out to examine
whether leptin is beneficial in AD patients.
However, several key factors need to be taken into account
when using leptin in future clinical studies. Thus identifying
which individuals are most likely to respond to leptin, and when
in the disease process a leptin-based therapy will be beneficial
is key. For instance, identifying individuals who have developed
resistance to leptin, as a consequence of midlife obesity,
may be pertinent as these individuals may be unresponsive
to leptin-based therapies. In contrast, leptin treatment may
be highly beneficial in AD patients with low baseline leptin
levels. As leptin receptors are expressed throughout the brain,
it is also vital that steps are taken to limit potential CNS
side effects associated with a leptin-based therapy. In this
respect, modification of the leptin molecule may enable specific
targeting of the key brain regions affected in AD and thus
enhance therapeutic efficacy. In support of this approach, a
recombinant methionyl human form of leptin (metreleptin) has
recently been developed, and gained FDA approval for use in
treating lipodystrophy (Paz-Filho et al., 2015). Several studies
have found that the whole leptin molecule is not required
as leptin fragments have reported biological activity and can
replicate the hypothalamic actions of leptin (Grasso et al.,
1997; Rozhavskaya-Arena et al., 2000). Consequently, another
approach may be to develop small leptin-like molecules. It would
have to be established that such leptin mimetics replicate the
full spectrum of cognitive enhancing and protective actions
of leptin. Moreover, retention of key properties of the whole
leptin molecule such as brain penetrability will be fundamental
for the future success of a leptin-based mimetic. However
recent studies in rodents have produced extremely promising
results as one leptin fragment, namely leptin116–130 was found to
replicate leptin action as it displayed powerful protective effects
on hippocampal synaptic function (Malekizadeh et al., 2017).
Indeed, leptin116–130 prevented the ability of Aβ to interfere with
hippocampal synaptic plasticity and promote neuronal toxicity.
Moreover, peripheral administration of leptin116–130 replicated
leptin’s cognitive enhancing properties as it improved the ability
of mice to performance specific episodic-like memory behavioral
tasks (Malekizadeh et al., 2017). This indicates not only that the
leptin116–130 fragment readily enters the brain but that it also
reaches the hippocampus where it markedly influences synaptic
physiology and function.
A ROLE FOR LEPTIN IN OTHER
NEURODEGENERATIVE DISORDERS?
In a manner similar to AD, increasing evidence indicates that
metabolic dysfunction is a prominent feature in several other
neurodegenerative diseases. Indeed, a link has been identified
between mid-life obesity and the risk and progression of
PD (Abbott et al., 2002; Procaccini et al., 2016). Alterations
in metabolic function related to mid-life obesity are also
associated with an increased likelihood of developing vascular
dementia (Kivipelto et al., 2005) and Huntington’s disease (HD;
Gaba et al., 2005; Procaccini et al., 2016). Clinical studies
have revealed almost a two fold increase in the incidence
of multiple sclerosis in obese (BMI >30) children compared
to those of normal body weight (Munger et al., 2009).
Several studies have observed alterations in the circulating
levels of leptin in both patients and in models of these
CNS disorders. Indeed, α-synuclein A53T transgenic mice,
that model familial PD, exhibit metabolic abnormalities and
hypoleptinemia (Rothman et al., 2014). In addition attenuated
plasma levels of leptin have been detected in HD (Pratley et al.,
2000; Popovic et al., 2004), and PD patients (Evidente et al.,
2001).
Several studies have found that an obese phenotype
exacerbates neurodegeneration in various disease models. For
instance, leptin deficient ob/ob mice treated with either
meth-amphetamine or kainic acid display significantly greater
neurotoxic damage and mortality rates than lean control mice
(Sriram et al., 2002). Moreover in a PD model, exposure
to the neurotoxin MPTP triggers far greater degeneration
of dopaminergic neurons in overfed obese mice than lean
littermates fed a normal diet (Choi et al., 2005). Degeneration
of dopamine neurons induced by central infusion of 6-OHDA
is also significantly elevated in diet-induced obese rodents
relative to lean littermates (Morris et al., 2010). Together
this suggests not only that leptin dysfunction contributes to
disease pathology, but also that the leptin system may be a
novel target for treatment of other neurodegenerative diseases
(Evidente et al., 2001; Aziz et al., 2007; Procaccini et al.,
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2016). However further work is required to evaluate fully
the potential use of the leptin system in treating these CNS
diseases.
CONCLUSION
It is well documented that the hippocampus is a key CNS target
for the hormone leptin and that the potential cognitive enhancing
effects of leptin are due to its actions at hippocampal synapses.
An established role for leptin is in its ability to regulate synaptic
efficacy at SC-CA1 synapses. However, recent evidence indicates
that the TA input to hippocampal CA1 neurons is also an
important functional target for this hormone. The regulatory
actions of leptin at excitatory TA-CA1 synapses is important
as the TA pathway is an early site for degeneration in AD,
and clinical studies demonstrate a link between leptin and an
increased risk of AD. In addition, treatment with leptin and
specific fragments of the whole leptin peptide have advantageous
effects in a range of systems that model AD, suggesting that
the leptin system is novel therapeutic target in AD. Although
there may be limitations to the therapeutic use of leptin, due to
development of leptin resistance in some individuals, it is clear
that clinical studies are needed to enable thorough assessment of
the therapeutic potential of the leptin system in AD patients. As
the risk of developing several other neurodegenerative disorders
is also linked to altered leptin function, it is feasible that targeting
the leptin system may also offer possible therapeutic benefit in
these CNS diseases.
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